New drug pricing authority to replace DRAP

In a significant and unexpected policy move, the federal government has opted to eliminate DRAP’s long-standing ability to set medicine pricing, marking a watershed moment in the country’s approach to pharmaceutical control.

To this effect, the Ministry of Health has announced the formation of a new, specialised council dedicated entirely to deciding the cost of prescriptions, particularly on life-saving treatments.

Prime Minister’s Orders

According to health department officials, the decision to take pricing powers away from the Drug Regulatory Authority of Pakistan was made on direct orders from Prime Minister Shehbaz Sharif, emphasizing the urgency and significance of this new path.

This news has prompted extensive interest and speculation in various industries as the new organisation is expected to offer new ideas and perhaps dramatic reforms to Pakistan’s medication pricing system.

A plan is currently being methodically written by a committee chaired by the law minister, demonstrating the government’s commitment to ensure a seamless and thorough transition. DRAP’s responsibility is now confined to determining the pricing of lifesaving pharmaceuticals but with the formation of this new board, the scope of pricing power is expected to increase dramatically.

How will this decision impact pharmaceuticals?

This decision has aroused numerous questions and created a sense of expectation among stakeholders since the new board’s larger mandate has the potential to cause significant changes in the pharmaceutical environment.

Will this result in more affordable pricing for the general people, or will it add new complexities? The nation waits with bated breath as this new chapter in drug policy unfolds.